General Updates

Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Date: 18 September 2026 Corporate relationship Department, National Stock Exchange of India, Limited BSE Limited, Exchange Plaza, 5th Floor, 1st Floor, Rotunda Building Plot No. C/1, G Block, Bandra-Kurla Complex, P.J Towers Dalal Street, Fort, Bandra (E), Mumbai 400001 Mumbai 400051 Stock Code: BSE – 530549 / NSE – SHILPAMED Dear Sir/Ma’am, SUB: USFDA Inspection of Shilpa Medicare Limited, Unit VII, Analytical Services Division, Hyderabad. REF: Intimation under regulation 30 of SEBI (LODR) Regulations 2015. This is to notify that the USFDA conducted Surveillance Inspection at Unit VII of Shilpa Medicare Limited, Analytical Services Division situated at Plot No.79, Road No. 15, Survey No.125, IDA Mallapur, Nacharam, Uppal Mandal, Medchal, Malkajgiri Dist. – 500076 Hyderabad, Telangana from 16 September 2026 to 18 September 2026. The inspection concluded with one procedural observation, which was neither a repeat observation nor related to data integrity. The Company will address the observation and respond within stipulated timeline. The details of the above Inspection (as required to be furnished pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated 30th January 2026) are enclosed as Annexure A. The above information is also available on the website of the Company www.vbshilpa.com For SHILPA MEDICARE LIMITED Ritu Tiwary Company Secretary & Compliance Officer Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Annexure A Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January 2026. Sr. No. Particulars Details 1. Name of the authority United States Food and Drug Administration (US FDA), USA 2. Nature and details of the action(s) taken, The United States Food and Drug Administration initiated or order(s) passed by the Authority (USFDA) has conducted a Surveillance Inspection (SI) at Analytical Services Division located at Hyderabad. The inspection was completed on 18 September 2026. At the conclusion of the inspection, the USFDA issued one observation, which was procedural in nature. 3. Date of receipt of direction or order, including 18 September 2026 any ad-interim or interim orders, or any other communication from the authority 4. Details of the violation(s)/ contravention(s) The inspection was completed on 18 September committed or alleged to be committed 2026. At the conclusion of the inspection, the USFDA issued one observation, which was procedural in nature. We will submit a comprehensive response to the USFDA within the stipulated timeline, addressing the observation with appropriate corrective and preventive actions. The Company is committed to maintaining the highest standards of quality and compliance across all its operations. 5 Impact on financial, operation or other We do not expect this development to have any activities of the listed entity, quantifiable in material impact on the current business monetary terms to the extent possible operations or existing supplies from this facility.